TXG (10x Genomics, Inc. Class A Common Stock) Stock Analysis - News
10x Genomics, Inc. Class A Common Stock (TXG) is a publicly traded Healthcare sector company. As of May 21, 2026, TXG trades at $23.71 with a market cap of $2.72B and a P/E ratio of -137.82. TXG moved +7.58% today. Year to date, TXG is +30.90%; over the trailing twelve months it is +164.10%. Its 52-week range spans $6.78 to $26.45. Analyst consensus is buy with an average price target of $24.10. Rallies surfaces TXG's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in TXG news today?
10x Genomics Sees Q1 Revenue of $150.8M, Launches Atera Platform: 10x Genomics reported Q1 revenue of $150.8 million, down 3% year-over-year but up 9% on an adjusted basis, and narrowed its net loss to $13.5 million from $34.4 million a year earlier. The company launched its Atera spatial whole-transcriptome platform, expects H2 2026 shipments, and ended Q1 with $539.8 million in cash and securities.
10x Genomics Sees Q1 Revenue of $150.8M, Launches Atera Platform: 10x Genomics reported Q1 revenue of $150.8 million, down 3% year-over-year but up 9% on an adjusted basis, and narrowed its net loss to $13.5 million from $34.4 million a year earlier. The company launched its Atera spatial whole-transcriptome platform, expects H2 2026 shipments, and ended Q1 with $539.8 million in cash and securities.
Does Rallies summarize TXG news?
Yes. Rallies summarizes TXG news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is TXG research on Rallies investment advice?
No. Rallies provides research, data, and educational context for TXG. It does not provide personalized investment advice.
